1.
Breast Dis
; 42(1): 315-318, 2023.
Article
in English
| MEDLINE
| ID: mdl-37807774
ABSTRACT
ER-/PR+ is a controversial subtype and is not formally recognised as molecular subtype of breast carcinoma. Few studies concluded that this subtype does not exist and is due to technical errors, however, in contrast others consider it to be distinct entity with different response to therapy and clinical outcome. It is also essential to know whether this subtype shows any distinct histomorphological features or prognosis.Therefore, the present two cases of controversial subtype ER-/PR+ breast cancer is being reported with both the cases showing neuroendocrinal differentiation.
Subject(s)
Breast Neoplasms , Humans , Female , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Breast Neoplasms/drug therapy , Receptors, Estrogen/genetics , Prognosis , Receptors, Progesterone/genetics , Receptor, ErbB-2 , Biomarkers, Tumor
2.
Transfus Clin Biol
; 30(2): 175-176, 2023 05.
Article
in English
| MEDLINE
| ID: mdl-36228970